Table 1.
Anti-HEV IgG seroprevalence rates determined by different commercial assays for different study cohorts.
| Study cohort | Wantai | Mikrogen | MP | Abbott | Adaltis | Dia.Pro | Others |
|---|---|---|---|---|---|---|---|
| General Population (%) | 16.90 | 10.11 | 6.50 | 2.29 | 8.72 | 4.35 | 12.48 |
| Sample size (n) | 88,204 | 1777 | 14,385 | 1077 | nd * | 5,176 | 3667 |
| Liver Disease (%) | 16.05 | 9.55 | 6.13 | 2.02 | 8.2 | 3.94 | 11.86 |
| Sample size (n) | nd * | 41 | 801 | 129 | nd * | nd * | 2000 |
| Transplant recipients (%) | 18.36 | 11.42 | 7.69 | 2.97 | 9.96 | 5.22 | 13.91 |
| Sample size (n) | 415 | 124 | 1328 | 262 | 64 | 448 | 52 |
| HIV (%) | 15.69 | 9.26 | 5.900 | 1.88 | 7.93 | 3.75 | 11.55 |
| Sample size (n) | 2047 | nd * | 1579 | 123 | 429 | 548 | 238 |
| Swine/Animal Contatct (%) | 28.51 | 20.13 | 15.26 | 8.37 | 18.25 | 11.82 | 23.21 |
| Sample size (n) | 101 | 709 | 1354 | 202 | 43 | nd * | 995 |
* For combinations of seroassays and study cohorts for which reported seroprevalence rates were not determined (nd), the seroprevalence was calculated by using a restricted maximum likelihood estimator model (R statistical platform and The metafor Package).